Skip to content
Back to search results

ThyPRO: Thyroid-Related Patient Reported Outcomes Scale

Introduced by
Torquil Watt, Jens Bjørner, Marianne Groenvold
Year
2009
Type
Patient self-report questionnaire
Family
Endocrine-specific quality of life
Font size

What does it do?

ThyPRO is a comprehensive patient-reported outcome measure assessing the quality of life impact of thyroid disease and its treatment across 13 dimensions.

Developed by Watt and colleagues in 2009, it is the most extensively validated thyroid-specific instrument, covering both physical and psychological domains relevant to patients with hyperthyroidism, hypothyroidism, and thyroid cancer.

The intuition behind the method

Thyroid disease substantially impacts quality of life beyond simple symptom control. ThyPRO captures this multidimensional burden—from physical symptoms (fatigue, weight fluctuations, temperature sensitivity) to psychological effects (anxiety, cognitive difficulties, mood disturbance) and social functioning. Unlike generic quality of life tools, it reflects what matters most to thyroid patients and clinicians managing their long-term care. The scale recognizes that optimal treatment extends beyond biochemical targets to encompass patient-reported well-being.

History

Developed 2009 by Watt, Groenvold, Bjørner and Danish collaborators at University of Copenhagen. Published in J Clin Endocrinol Metab 94(9):3572-3580 (2009). Initial validation included 2,000+ thyroid patients across Graves' disease, Hashimoto thyroiditis, and thyroid cancer populations. Short form (ThyPRO-39) developed 2012 via Rasch analysis; validation completed 2012-2016. Recognized by the American Thyroid Association; adopted in major clinical trials (TAPAS, REACT). Translated into 20+ languages with cross-cultural validation. Continues to evolve with item banking and computerized adaptive testing (CAT-ThyPRO) under development.

When to use it

ThyPRO is indicated for: (1) Monitoring quality of life in patients with Graves' disease, hashimoto thyroiditis, or thyroid cancer during treatment; (2) Research evaluating interventions for thyroid disease (thyroidectomy, radioiodine, antithyroid drugs); (3) Shared decision-making when balancing treatment intensity vs. quality of life burden; (4) Identifying patients with persistent symptom burden despite biochemical euthyroidism; (5) Evaluating long-term hypothyroid or hyperthyroid symptom persistence. Appropriate for adults aged 18+; pediatric versions under development. Used internationally in clinical trials and increasingly in routine endocrinology practice.

Limitations and considerations

  • 4-week recall period may miss acute symptom fluctuations in patients with rapid mood or energy changes.
  • Limited data comparing responsiveness across treatment modalities (surgical, radioiodine, pharmacological) in head-to-head prospective studies.
  • Psychological domains (anxiety, irritability) show moderate-high overlap; factor structure remains under refinement in some language versions.
  • Ceiling effects observed in some domains among patients with mild disease or well-controlled symptoms; may limit sensitivity in quiescent populations.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Multidimensional coverage: 13 distinct domains capture the full symptom and functional burden of thyroid disease, not collapsible to a single dimension.
  • Strong psychometric evidence: Extensively validated across multiple languages and patient populations; high internal consistency (Cronbach alpha 0.80-0.95 per domain) and test-retest reliability.
  • Responsiveness to clinical change: Sensitive to symptom improvement with treatment; published MCID values enable clinically meaningful difference detection in trials and practice.
  • Thyroid-specific content: Developed with patient input to reflect thyroid disease-relevant concerns (e.g., cold/heat intolerance, eye symptoms in Graves' disease), missing from generic QoL measures.

Applications

  • Clinical trials: Primary or secondary endpoint in hypothyroidism, hyperthyroidism, and thyroid cancer treatment trials evaluating symptom burden reduction.
  • Routine endocrinology practice: Baseline and periodic monitoring of patients post-thyroidectomy or radioiodine to assess quality of life trajectory and guide levothyroxine dose adjustments.
  • Shared decision-making: Quantifying quality of life trade-offs when counseling patients on surgical vs. medical management or intensity of TSH suppression in thyroid cancer.
  • Research epidemiology: Population surveys investigating prevalence of long-term thyroid-related morbidity and predictors of persistent symptoms despite biochemical euthyroidism.
  • Comorbidity assessment: Distinguishing thyroid-related symptoms from depression, anxiety disorders, or somatic symptom disorder in patients with multiple diagnoses.

How it works

How it works

1

ThyPRO-85 comprises 85 items with a 4-week recall period; ThyPRO-39 is a validated short form with 39 items. Items are rated on Likert scales (typically 4-point: 'not at all' to 'very much'). Respondents rate frequency or bothersomeness of symptoms and impacts. Administration time: 10-15 minutes (short form) to 20-25 minutes (full version). Self-administered by pencil-and-paper or electronic means; interviewer administration acceptable. Requires ability to read and comprehend at adult level.

Formula
Complete all items; no time limit; self-administered or interview-administered
2

Raw item responses (0-3 or 1-4) are converted to 0-100 scale for each of the 13 domains: (1) Hyperthyroid symptoms, (2) Hypothyroid symptoms, (3) Tiredness/Fatigue, (4) Cognitive impairment, (5) Anxiety, (6) Irritability/Impatience, (7) Emotional lability, (8) Weight gain, (9) Cold intolerance, (10) Heat intolerance, (11) Eye symptoms, (12) Skin symptoms, (13) Goiter symptoms. Domain scores are derived by averaging relevant items and transforming to 0-100. No total composite score; interpretation focuses on individual domains. Higher scores = worse quality of life in that domain.

Formula
Convert raw responses to 0-100 scale per domain; calculate domain means
3

Scores on each 0-100 domain scale are interpreted as: 0-20 = minimal impact, 21-40 = mild impact, 41-60 = moderate impact, 61-80 = severe impact, 81-100 = very severe impact. Minimal Clinically Important Difference (MCID) typically ranges 8-15 points depending on domain. Responsiveness to treatment changes: ThyPRO shows good sensitivity to improvement with therapy. Comparative domain profiles reveal predominant symptom clusters (e.g., hypothyroid vs. hyperthyroid patterns). Used to monitor longitudinal outcomes in clinical trials and individual patient management.

Formula
Higher scores indicate worse quality of life; evaluate domains individually and overall pattern

Common pitfalls

  • Confusing higher scores with better outcomes: ThyPRO is reverse-scored (0-100 with 100 = worst), unlike some other scales. Always verify direction before interpreting.
  • Using total score: ThyPRO-85 and ThyPRO-39 do not yield a single summary score. Clinicians unfamiliar with the instrument sometimes attempt to average across domains, losing specificity of symptom domains.
  • Assuming score stability across TSH ranges: Symptom improvement lags biochemical correction; thyroid antibody status, comorbidities, and psychological factors independently affect domain scores beyond TSH alone.

Frequently asked questions

Is ThyPRO-39 as reliable as ThyPRO-85?

Yes. The short form (ThyPRO-39) retains excellent psychometric properties (Cronbach alpha >0.80 per domain) with minimal loss of information compared to the full 85-item version. ThyPRO-39 is recommended for routine clinical use due to shorter administration time (10 minutes vs. 20 minutes) without sacrificing measurement validity.

What TSH target corresponds to best ThyPRO scores?

No fixed TSH threshold predicts ThyPRO response. Patients show wide variation: some achieve good quality of life at TSH 1-2 mIU/L, others report persistent fatigue and cognitive symptoms despite TSH in target range. Individual titration based on both TSH and ThyPRO domains is recommended, particularly for patients with residual hypothyroid complaints at standard TSH targets.

Can ThyPRO be used before diagnosis (screening)?

No. ThyPRO is designed for diagnosed thyroid disease patients and assesses disease-related quality of life. It is not a screening tool for thyroid dysfunction. Use TSH and thyroid antibodies for diagnostic screening.

Are there normative data for comparison to general population?

Yes. Published reference values from >2,000 Danish thyroid patients show mean domain scores by diagnosis (Graves', Hashimoto, post-thyroidectomy). General population comparisons available in peer-reviewed literature; most thyroid populations score 40-60 (moderate impact) on fatigue and emotional domains at baseline.

Related methods

Sources

  1. Watt, T., Bjorner, J. B., Groenvold, M., et al. (2009). Establishing construct validity for the thyroid-related patient reported outcomes (ThyPRO): An initial examination. J Clin Endocrinol Metab, 94(9), 3572-3580.

    Open publication reference
    Copied.
  2. Watt, T., Groenvold, M., Bjorner, J. B., et al. (2012). Validity and responsiveness of the Danish version of ThyPRO and comparison with the Perceived Deficits Questionnaire. Value Health, 15(3), 528-534.

    Open publication reference
    Copied.